Dhanuka Q1 PAT sinks 35% YoY to ₹36 Cr as revenue slips 13%, margins compress hard

Dhanuka Agritech opened FY27 with a weak, demand-led print: standalone revenue fell 12.6% YoY to ₹461.9 Cr and net profit dropped 34.6% YoY to ₹36.3 Cr (EPS ₹8.06 vs ₹12.31). This badly misses street and management's own set-up — Uniresearch had pencilled in ₹564 Cr revenue (+6.9%) and ₹64 Cr PAT (+14.3%), and on the Q1 FY26 concall management had guided to low-double-digit FY27 revenue growth on the full-year impact of acquired Bayer products and re-introduced biostimulants. Q1 delivered the opposite of that guidance on the topline, with the agri-input cyclicality management always flags (monsoon, pest, crop patterns) working against it this quarter. The damage is operating deleverage, not a one-off: with no exceptional items on either side, the profit fall is genuine. Net margin compressed to 7.9% from 10.5% a year ago, and EBIT-level margin thinned as expenses (₹422.2 Cr) fell far less than revenue — employee cost (₹46.5 Cr) and other expenses (₹60.9 Cr) were essentially flat YoY against a shrunken topline, while other income of ₹8.9 Cr and lower finance cost cushioned only marginally. The sequential optics are worse still (PAT ₹36.3 Cr vs ₹97.8 Cr in Q4) but that is a seasonality artifact — Q4 is Dhanuka's strong rabi quarter and is not the right comparison; YoY is the clean read here. The board paired the soft result with two capital moves signalling continued confidence in the runway: approval of up to ₹200 Cr for a new 23,000 MT/annum pesticide plant at Nagpur (operational by Mar/Apr 2028, funded by internal accruals/debt) to shorten lead times into South, East and Central India, and a ₹15 Cr loan to the employee trust for the SAR 2026 plan — on top of the ₹70 Cr buyback executed during the quarter. Q2 (kharif) will test whether the guided low-double-digit growth and Bayer/biostimulant contribution actually materialise, or whether the FY27 outlook needs to be reset lower.